38 results about "Istradefylline" patented technology

The invention discloses an istradefylline synthesis process comprising the following steps: a compound I is prepared from 1,3-diethylformamide and cyanoacetic acid in acetic anhydride; the compound I is added into acetic acid, and the mixture is stirred for 30min; sodium nitrite is added, and thus a compound II is prepared; hydrogen gas is introduced into the compound II and methanol, such that a compound III is obtained; the compound III, 3-(3,4-dimethoxyl-phenol)-acryloyl chloride, sodium hydroxide and dichloromethane are prepared into a compound IV; the compound IV and sodium hydroxide are added into 1,4-dioxane, such that a compound V is prepared; the compound V, dimethyl carbonate, DMF, and sodium hydroxide are subjected to a methylation reaction; and cooling, suction filtration and washing are carried out, such that istradefylline is obtained. With the process, the final product can be obtained with high efficiency; the synthesis route is simple; purification is easy; the application of a highly toxic or neurotoxic methylation reagent, such as iodomethane, is avoided. The process is suitable for industrialized productions, and assists in reducing the production cost.

The invention relates to a preparation method of an istradefylline intermediate, which comprises the following steps: by using (E)-1,3-diethyl-6-amino-5-(3,4-dimethoxyphenylacryloyl)amino-uracil (YQ-1) as a raw material and 1,4-dioxane as a solvent, heating under the alkaline condition of a NaOH water solution to perform condensation and cyclization to generate (E)-8-[2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-3,7-dihydro-1H-purinyl-2,6-dione (YQ-2), and carrying out rotary evaporation, acid regulation and vacuum filtration to obtain a YQ-2 crude product; and by using toluene as a solvent, recrystallizing the YQ-2 crude product to obtain the YQ-2 refined product. The method has the advantages of simple route, accessible raw materials and mild conditions, and is convenient to operate; the total yield is greater than 85%, and the purity is up to higher than 97%; and thus, the method is suitable for scale-up production.

The invention discloses a new crystal form of istradefylline and a preparation method thereof. The powder X-ray diffraction of the new crystal form of istradefylline has characteristic peaks where 2theta is equal to 10.4 +/-0.2 degrees, 11.2 +/-0.2 degrees, 15.8 +/-0.2 degrees, 24.6 +/-0.2 degrees, and 25.2 +/-0.2 degrees. The new crystal form of istradefylline is thermodynamically stable and has obviously improved solubility in water; the new crystal form of istradefylline, which is crystalline solid powder having a small particle size, is good in fluidity, so that the problem of non-uniform crystal condensation and dispersion in process operation of a preparation can be solved; the new crystal form of istradefylline is more suitable for storage and for use as a bulk pharmaceutical chemical; and a new way is provided for the preparation of istradefylline drugs.

The invention relates to a new crystal form of istradefylline and a preparation method thereof; the new crystal form IV has a powder X-ray diffraction pattern having main characteristic absorption peaks at diffraction angles (2theta) of 5.763 degrees, 6.958 degrees, 10.599 degrees, 10.999 degrees, 13.944 degrees, 15.647 degrees, 19.513 degrees, 21.004 degrees, 21.400 degrees, 24.426 degrees and 28.320 degrees. The invention also discloses the preparation method of the new crystal form IV which has simple preparation process and relatively good stability and conforms to medicinal requirements.

The invention relates to the technical field of pharmaceutical chemistry, and particularly relates to a preparation method and use of istradefylline; specifically, with 1,3-diethyl formamide and cyanoacetic acid as raw materials, istradefylline is prepared through cyclization, nitration, reduction, condensation, cyclization, methylation reaction and other steps; the preparation method provided by the invention is simple, high in production efficiency and wide in application prospect.

The invention discloses an orally disintegrating tablet containing Istradefylline and a preparation method thereof. The tablet contains a water-soluble filler, a binder, a disintegrating agent, a lubricant, and an odor mask. A solid dispersion technology is employed to improve the taste. The tablet has the characteristics of good taste, good oral compliance, rapid onset, and is applicable to the treatment of Parkinson's disease. The invention also provides a preparation method. The method has simple process and low cost, and belongs to the medical technical fields of medical science and pharmacy.

The invention provides an istradefylline preparation method. 1,3-diethyl-5,6-diaminouracil used as a starting material undergoes an acylation reaction, a ring formation reaction and a methylation reaction to prepare istradefylline. The ring formation reaction and the methylation reaction are carried out simultaneously, an istradefylline intermediate (E)-1,3-diethyl-6-amino-5-(3,4-dimethoxyphenylacryloyl)aminouracil is reacted by adding a methylating agent in an alkaline environment, and the obtained solution is filtered and crystallized to obtain the istradefylline. The ring formation and themethylation are simultaneously carried out, and the methylation is immediately carried out after the completion of the ring formation to promote the forward proceeding, so the yield of the product isincreased, large amounts of organic solvents are saved, and the generation amount of an organic waste liquid is reduced; and the method has the advantages of simplicity in operation, and high reactionconversion rate, and allows the purity of the product to be higher than 99%.

The invention relates to a preparation method for Istradefylline represented by a formula (I) shown in the description. The method comprises the following steps: subjecting 6-amino-1,3-diethyl-5-nitroso-1H-pyrimid-2,4-dione represented by a formula (II) shown in the description, which serves as a raw material, to catalytic reduction and salt forming, so as to obtain 5,6-diamino-1,3-diethyl-1H-pyrimid-2,4-dione hydrochloride represented by a formula (III) shown in the description; then, carrying out acetylation on the compound (III), so as to obtain N-(6-amino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimid-5-yl)acetamide represented by a formula (IV) shown in the description; carrying out further ring closing, so as to obtain 1,3-diethyl-8-methyl-1H-purin-2,6(3H,7H)-dione represented by a formula (V) shown in the description; and carrying out methylation on the compound (V) firstly, and then, subjecting the methylation product to a condensation reaction with veratraldehyde represented by a formula (VII) shown in the description, thereby obtaining the end product Istradefylline. According to the novel preparation method for the Istradefylline, provided by the invention, raw materials, which are readily available industrially and are low in price, are used, the production process is more environmentally friendly, and the obtained product Istradefylline is high in yield and purity, thereby having a relatively high practical value.

The invention relates to an istradefylline raw material drug and a preparation method thereof. Specifically, the invention relates to an istradefylline raw material drug. A compound shown in formula III is not higher than 0.5% and is a medicine preparation consisting of the istradefylline raw material drug and a pharmacologically acceptable carrier and/ or diluent. The raw material drug and the preparation thereof have better safety, effectiveness and stability. The formula III is shown in the description.

The present invention provides a therapeutic and/or prophylactic agent and the like, comprising istradefylline as an active ingredient, for Lewy body disease (for example, Parkinson's disease dementia, diffuse Lewy body disease, dementia with Lewy bodies, movement disorder associated with Lewy body disease and the like).

The invention relates to a pharmaceutical composition and application thereof, specifically to a pharmaceutical composition containing istradefylline and application thereof, belonging to the field of medicine. To overcome disadvantages of conventional neurodegenerative disease therapeutics in neurodegenerative disease therapeutics, especially the defects of great side effect and high treatment cost of therapeutics for the Parkinson disease, the invention provides the pharmaceutical composition containing istradefylline. When the pharmaceutical composition containing istradefylline is applied to treatment of the Parkinson disease, side-effects of drugs in treatment of the Parkinson disease are substantially reduced, treatment cost for the Parkinson disease is lowered down at the same time, and a breakthrough is made to the golden rule that levodopa has to be used in clinical treatment of the Parkinson disease; thus, the pharmaceutical composition containing istradefylline has good medical application prospects.

The invention discloses a preparation method for a medicine-istradefylline crystal form II for treating Parkinson. After the istradefylline and mixed solvent are mixed, mixture is heated to 70-90 DEGC to be dissolved, then, the mixture is quickly cooled to 0-5 DEG C, and crystallization is carried out to obtain the istradefylline crystal form II for treating Parkinson. The stability of the istradefylline crystal form II for treating Parkinson is equivalent to the stability of the traditional istradefylline crystal form II, yield and purity are higher, the quality of a product is greatly improved, in addition, the bioavailability of the istradefylline crystal form II can be improved so as to be favorable for the medicine processing and user in a medicine composite, and meanwhile, qualitative and quantitative information can be provided so as to have an important meaning for further researching the curative effect of the solid medicine.

The invention discloses an application of istradefylline in preparation of drugs for reversing drug resistance of tumor cells, and relates to the technical field of treatment of drug resistance of tumor cells. The istradefylline and the paclitaxel are combined to be used for preparing the medicine for reversing the drug resistance of the tumor paclitaxel. The researches find that the istradefylline can significantly reduce the expression level of MDR1 genes and proteins, and the combination of the istradefylline and the chemotherapeutic drug paclitaxel can significantly improve the sensitivity of drug-resistant cells to the chemotherapeutic drug, so that the tumor drug resistance is reversed, and the curative effect is greatly improved. Animal experiments also prove that istradefylline can effectively inhibit the growth speed of subcutaneous tumors of a drug-resistant animal model and reverse the drug resistance of paclitaxel. The results show that the istradefylline is combined with the paclitaxel, so that the treatment effect of the paclitaxel on tolerant tumors can be effectively enhanced. The condition that many malignant tumor cells have drug resistance to paclitaxel is clinically found, and therefore istradefylline has good development value and application prospects.

Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefylline are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.

The invention discloses an istradefylline containing pharmaceutical composition. The composition is prepared from, by weight, 20-50 parts of istradefylline, 10-20 parts of puerarin, 5-12 parts of starch, 1-9 parts of low-substituted hydroxypropyl cellulose, 2-6 parts of magnesium stearate, 2-8 parts of antioxidant, 3-5 parts of mannitol, 2-10 parts of superfine silica powder, 2-10 parts of chitosan, 2-8 parts of sodium alginate and 3-10 parts of lactose. A preparation process of the composition includes the steps of weighing and evenly mixing istradefylline, puerarin, starch, low-substituted hydroxypropyl cellulose, magnesium stearate, antioxidant, mannitol, superfine silica powder, chitosan, sodium alginate and lactose according to the amounts in the formula, additionally adding a proper amount of 60% ethyl alcohol to mixed powder to be evenly mixed to prepare a soft material, conducting granulating through a 16-mesh screen, conducting drying at 60 DEG C or below, conducting size stabilizing after drying is completed, evenly mixing granules with dry particles, and conducting tabletting to obtain the composition. The composition has the advantage of treating the Parkinson's disease.

A therapeutic agent for Parkinson's disease containing istradefylline as an effective ingredient being characterized in exhibiting more expression of a shortening effect of the OFF time by administration to a patient of Parkinson's disease of 65 or more years old as compared with administration to a patient of Parkinson's disease of younger than 65 years old.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a preparation and purification method for removing methyl impurities from istradefylline. Istradefylline is used as a raw material to prepare three high-purity demethylated impurity compounds I, II and III, the method is simple in process, easy to operate, simple in purification and high in yield, the prepared impurities are high in purity, and qualified impurity reference substances can be provided for quality control of istradefylline. The istradefylline impurity reference substance prepared by the invention can provide an important reference basis for monitoring the impurity in the research and development of an istradefylline process, improves the quality monitoring level of istradefylline, and has great significance and practical value for the development of medicinal istradefylline.

The invention discloses a synthetic method of istradefylline, and belongs to the technical field of medicines. The synthesis method of the istradefylline mainly comprises the steps of acylation, ringclosing, methylation and the like. The method is high in yield, simple in step and single in solvent, wherein reaction selectivity can be effectively promoted and side reactions are reduced; after ring closing is finished, dimethyl sulfate is dropwise added for a methylation reaction by means of the alkalinity of dimethyl sulfate. The method can be more thorough and cleaner than a dimethyl carbonate reaction in the prior art. The whole process can be carried out in one reaction kettle, wherein the solvent only relates to ethanol and subsequently refined methanol and can be recycled, so that the synthesis method has advantages of high reaction selectivity and yield.